# OR502

Source: https://onco.cc/drugs/or502/  
OnCo record `or502` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

OR502 is a monoclonal antibody from OncoResponse, Inc., in registered phase 2 trials for metastatic cancer, melanoma, non-small-cell lung cancer.

## Summary

OR502 is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by OncoResponse, Inc., in metastatic cancer, melanoma, non-small-cell lung cancer, small-cell lung cancer. A monoclonal antibody, as described in the registry record. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest; registry-only
- Code: OR502
- Modality: Monoclonal antibody
- Mechanism: A monoclonal antibody, as described in the registry record.

## Sources

- ClinicalTrials.gov: trials of OR502: https://clinicaltrials.gov/search?intr=OR502

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/), [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- trials: [A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents](https://onco.cc/trials/nct06090266/)

---
JSON: https://onco.cc/api/v1/entities/or502.json